Breast Cancer Clinical Trial

Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer

Summary

The main purpose of this study is to compare progression free survival in patients treated with AZD8931 given in combination with anastrozole versus anastrozole alone. The secondary objective is to investigate the safety and tolerability of AZD8931 given in combination with anastrozole.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patients that have locally advanced or metastatic breast cancer. Lesions should not be amenable to surgery or radiation of curative intent
Hormone therapy-naive
Estimated life expectancy of more than 12 weeks

Exclusion Criteria:

Last dose of prior anti-cancer therapy received within 14 days (or longer if required)
Any eye injury or corneal surgery within 3 months prior to receiving first dose of study drug.
Currently receiving (and unwilling to discontinue) oestrogen replacement therapy. (last dose <7 days prior to randomisation)

Study is for people with:

Breast Cancer

Phase:

Phase 2

Estimated Enrollment:

482

Study ID:

NCT01151215

Recruitment Status:

Terminated

Sponsor:

AstraZeneca

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Research Site
Lake Success New York, , United States
Research Site
Belo Horizonte , , Brazil
Research Site
Goiânia , , Brazil
Research Site
Ijuí , , Brazil
Research Site
Porto Alegre , , Brazil
Research Site
Rio de Janeiro , , Brazil
Research Site
Sao Paulo , , Brazil
Research Site
São Paulo , , Brazil
Research Site
Vancouver British Columbia, , Canada
Research Site
Ottawa Ontario, , Canada
Research Site
Montreal Quebec, , Canada
Research Site
Brno , , Czech Republic
Research Site
Olomouc , , Czech Republic
Research Site
Praha 2 , , Czech Republic
Research Site
Praha 4 , , Czech Republic
Research Site
Helsinki , , Finland
Research Site
Tampere , , Finland
Research Site
Turku , , Finland
Research Site
Bangalore , , India
Research Site
Hyderabad , , India
Research Site
Mumbai , , India
Research Site
Pune , , India
Research Site
Trivandrum , , India
Research Site
Vellore , , India
Research Site
Niigata-shi , , Japan
Research Site
Osaka-shi , , Japan
Research Site
Ota-shi , , Japan
Research Site
Sapporo-shi , , Japan
Research Site
Seoul , , Korea, Republic of
Research Site
Durango , , Mexico
Research Site
Juchitan , , Mexico
Research Site
Merida , , Mexico
Research Site
Monterrey , , Mexico
Research Site
Callao , , Peru
Research Site
Lima , , Peru
Research Site
Piura , , Peru
Research Site
Iloilo City , , Philippines
Research Site
Lipa City , , Philippines
Research Site
Pasay City , , Philippines
Research Site
Quezon City , , Philippines
Research Site
Białystok , , Poland
Research Site
ElblÄ…g , , Poland
Research Site
Kraków , , Poland
Research Site
Warszawa , , Poland
Research Site
Kuzmolovsky , , Russian Federation
Research Site
Moscow , , Russian Federation
Research Site
Saint Petersburg , , Russian Federation
Research Site
Durban , , South Africa
Research Site
Pretoria , , South Africa
Research Site
Taipei , , Taiwan
Research Site
Bangkok , , Thailand
Research Site
Songkla , , Thailand
Research Site
Dnipropetrovsk , , Ukraine
Research Site
Lviv , , Ukraine
Research Site
Birmingham , , United Kingdom
Research Site
Bournemouth , , United Kingdom
Research Site
Coventry , , United Kingdom
Research Site
Leicester , , United Kingdom
Research Site
London , , United Kingdom
Research Site
Nottingham , , United Kingdom
Research Site
Surrey , , United Kingdom
Research Site
Wythenshawe, Manchester , , United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 2

Estimated Enrollment:

482

Study ID:

NCT01151215

Recruitment Status:

Terminated

Sponsor:


AstraZeneca

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider